Now that Pfizer has had two major deals dashed by government resistance, Pfizer CEO Ian Read says he will not be doing any more tax inversions.

Investors have indicated they support Pfizer CEO Ian Read and his strategies despite a second failed attempt at a big tax inversion deal.

January 27, 2016By Karl Thiel for BioSpace.com   Not that you need to be reminded of this, but… For the stock market, this has been the worst kickoff ever to a new year. And for biotech, it has been much, much worse. The Nasdaq Biotech Index plummeted over 17 percent in the first eight trading […]

After three weeks of speculation New York-based Pfizer Inc. (PFE) announced today that it was merging with Dublin, Ireland-based Allergan plc (AGN). Board members for both companies unanimously voted Sunday to approve the deal, which will have a total enterprise value of about $160 billion.   The deal will be a stock transaction of about […]

Yesterday’s announcement by the U.S. Treasury Department of rules changes to make tax inversions more difficult, might stop the pending Pfizer Inc. (PFE)-Allergan, Inc. (AGN) deal, but insiders are indicating it may be structured differently to avoid those changes. Predominantly, there is speculation that instead of Pfizer acquiring Allergan, the deal will be structured in […]